| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C L Ronchi, F Coletti, E Fesce, L Montefusco, C Ogliari, E Verrua, P Epaminonda, E Ferrante, E Malchiodi, V Morelli, P Beck-Peccoz, M Arosi. Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly. Journal of endocrinological investigation. vol 32. issue 6. 2010-02-17. PMID:19494714. |
cancer risk factors, duration of acromegaly, gh and igf-i levels, igf binding protein 3 and igf-ii concentrations, metabolic parameters, tumor markers, colonic lesions by total colonoscopy, and sb lesions by vce were investigated. |
2010-02-17 |
2023-08-12 |
human |
| Agatha A van der Klaauw, Jeroen J Bax, Ferdinand Roelfsema, Marcel P M Stokkel, Gabe B Bleeker, Nienke R Biermasz, Johannes W A Smit, Johannes A Romijn, Alberto M Pereir. Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary. vol 12. issue 4. 2010-02-01. PMID:19521779. |
limited effects of growth hormone replacement in patients with gh deficiency during long-term cure of acromegaly. |
2010-02-01 |
2023-08-12 |
human |
| Agatha A van der Klaauw, Jeroen J Bax, Ferdinand Roelfsema, Marcel P M Stokkel, Gabe B Bleeker, Nienke R Biermasz, Johannes W A Smit, Johannes A Romijn, Alberto M Pereir. Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary. vol 12. issue 4. 2010-02-01. PMID:19521779. |
the aim of this study was to assess the effects of replacement with recombinant human growth hormone (rhgh) in patients with gh deficiency (ghd) after treatment of acromegaly. |
2010-02-01 |
2023-08-12 |
human |
| Agatha A van der Klaauw, Jeroen J Bax, Ferdinand Roelfsema, Marcel P M Stokkel, Gabe B Bleeker, Nienke R Biermasz, Johannes W A Smit, Johannes A Romijn, Alberto M Pereir. Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary. vol 12. issue 4. 2010-02-01. PMID:19521779. |
sixteen patients (8 men, age 56 years), treated for acromegaly by surgery and radiotherapy, with an insufficient gh response to insulin-induced hypoglycaemia, were treated with 1 year of rhgh replacement. |
2010-02-01 |
2023-08-12 |
human |
| Niels Moller, Mikkel H Vendelbo, Ulla Kampmann, Britt Christensen, Michael Madsen, Helene Norrelund, Jens O Jorgense. Growth hormone and protein metabolism. Clinical nutrition (Edinburgh, Scotland). vol 28. issue 6. 2010-02-01. PMID:19773097. |
the importance of gh is further substantiated by the observations that adult patients with gh-deficiency are obese and have reduced lbm, and impaired physical performance and acromegaly is characterised by increased lbm and decreased fat mass. |
2010-02-01 |
2023-08-12 |
Not clear |
| Ignacio Bernabeu, Cristina Alvarez-Escolá, Celsa Quinteiro, Tomás Lucas, Manel Puig-Domingo, Manuel Luque-Ramírez, Paz de Miguel-Novoa, Eva Fernandez-Rodriguez, Irene Halperin, Lourdes Loidi, Felipe F Casanueva, Mónica Marazuel. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. The Journal of clinical endocrinology and metabolism. vol 95. issue 1. 2010-02-01. PMID:19850678. |
the deletion of exon 3 in the gh receptor (ghr) has been associated with a different biochemical picture and response to therapy in acromegaly. |
2010-02-01 |
2023-08-12 |
Not clear |
| Philippe Chanson, Sylvie Salenave, Peter Kamenicky, Laure Cazabat, Jacques Youn. Pituitary tumours: acromegaly. Best practice & research. Clinical endocrinology & metabolism. vol 23. issue 5. 2010-02-01. PMID:19945023. |
excessive production of the growth hormone (gh) is responsible for acromegaly. |
2010-02-01 |
2023-08-12 |
Not clear |
| Ashley S Izzard, Michael Emerson, Sukhpal Prehar, Ludwig Neyses, Peter Trainer, Edward O List, John J Kopchick, Anthony M Heagert. The cardiovascular phenotype of a mouse model of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 19. issue 5. 2010-01-15. PMID:19269870. |
direct comparison of a mouse model of acromegaly to a mouse model of laron's syndrome allowed us to carry out detailed phenotyping and better understand the role gh plays in the circulatory system. |
2010-01-15 |
2023-08-12 |
mouse |
| M J E Wassenaar, N R Biermasz, A M Pereira, A A van der Klaauw, J W A Smit, F Roelfsema, T van der Straaten, M Cazemier, D W Hommes, H M Kroon, M Kloppenburg, H-J Guchelaar, J A Romij. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. The Journal of clinical endocrinology and metabolism. vol 94. issue 12. 2010-01-05. PMID:19864451. |
the aim of the study was to evaluate the impact of the genomic deletion of exon 3 of the gh receptor (d3ghr) on long-term clinical outcome of acromegaly in a well-characterized cohort of patients with long-term remission of acromegaly. |
2010-01-05 |
2023-08-12 |
Not clear |
| Richard A Feelders, Leo J Hofland, Maarten O van Aken, Sebastian J Neggers, Steven W J Lamberts, Wouter W de Herder, Aart-Jan van der Lel. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. vol 69. issue 16. 2009-12-29. PMID:19852525. |
acromegaly is a chronic disease with signs and symptoms due to growth hormone (gh) excess. |
2009-12-29 |
2023-08-12 |
Not clear |
| Richard A Feelders, Leo J Hofland, Maarten O van Aken, Sebastian J Neggers, Steven W J Lamberts, Wouter W de Herder, Aart-Jan van der Lel. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. vol 69. issue 16. 2009-12-29. PMID:19852525. |
new developments in the medical therapy of acromegaly include the universal somatostatin receptor agonist pasireotide, which has a broader affinity for all somatostatin receptor (sst) subtypes compared with the currently available somatostatin analogues with preferential affinity for the sst2 receptor, and chimeric compounds that interact with both somatostatin and dopamine receptors with synergizing effects on gh secretion. |
2009-12-29 |
2023-08-12 |
Not clear |
| A L Barka. Acromegaly. Trends in endocrinology and metabolism: TEM. vol 3. issue 6. 2009-12-14. PMID:18407101. |
in the majority of cases, acromegaly is due to gh hypersecretion by a somatotroph pituitary tumor. |
2009-12-14 |
2023-08-12 |
Not clear |
| W Matthew Widdowson, Marie-Louise Healy, Peter H Sönksen, James Gibne. The physiology of growth hormone and sport. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 19. issue 4. 2009-12-14. PMID:19505835. |
the model of acromegaly provides evidence that long-term gh excess does not result in improved performance but it is possible that a "window" exists in which the protein anabolic effects of supraphysiologic gh might be advantageous. |
2009-12-14 |
2023-08-12 |
human |
| F Castinetti, A Saveanu, I Morange, T Bru. Lanreotide for the treatment of acromegaly. Advances in therapy. vol 26. issue 6. 2009-12-11. PMID:19533047. |
the drug shows high binding affinity for somatostatin receptors, sstr2 and sstr5, which is the primary mechanism considered to be responsible for decreasing gh secretion and gh cell proliferation in acromegaly. |
2009-12-11 |
2023-08-12 |
Not clear |
| C Berg, T E Wessendorf, F Mortsch, M Forsting, H Teschler, T Weischer, K Mann, B Saller, B L Herrman. Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. European journal of endocrinology. vol 161. issue 6. 2009-12-11. PMID:19773369. |
we investigated the influence of disease activity on tongue volume and sleep apnoea treated with the gh receptor antagonist pegvisomant in poorly controlled patients with acromegaly under octreotide. |
2009-12-11 |
2023-08-12 |
Not clear |
| David J Moore, Yaser Adi, Martin J Connock, Sue Baylis. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC endocrine disorders. vol 9. 2009-12-11. PMID:19814797. |
acromegaly, an orphan disease usually caused by a benign pituitary tumour, is characterised by hyper-secretion of growth hormone (gh) and insulin-like growth factor i (igf-1). |
2009-12-11 |
2023-08-12 |
Not clear |
| B L Herrmann, M Severing, A Schmermund, C Berg, Th Budde, R Erbel, K Man. Impact of disease duration on coronary calcification in patients with acromegaly. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 117. issue 8. 2009-12-09. PMID:19373755. |
the prospective study included 30 patients with acromegaly (mean age 53+/-14 year; 16 females, 14 males; bmi 28.1+/-3.6 kg/m (2); mean+/-sd), 12 patients had active disease (igf-1 751+/-338 microg/l; gh 25.6+/-36.4 microg/l), 9 were well-controlled (igf-1 157+/-58 microg/l; gh 1.8+/-1.1 microg/l) under somatostatin analogue octreotide (n=5), dopamine agonists (n=2), and the gh receptor antagonist pegvisomant (n=2; gh levels were not determined in this subgroup) and 9 were cured igf-1 (148+/-57 microg/l; gh 0.5+/-0.2 microg/l). |
2009-12-09 |
2023-08-12 |
Not clear |
| Pedro W S Rosário, Mariana S Furtad. Growth hormone after oral glucose overload: revision of reference values in normal subjects. Arquivos brasileiros de endocrinologia e metabologia. vol 52. issue 7. 2009-12-01. PMID:19082302. |
the evaluation of growth hormone (gh) secretion continues to be important in acromegaly and the nadir gh (n-gh) level in the oral glucose tolerance test (ogtt) is the gold standard for the demonstration of secretory autonomy of this hormone. |
2009-12-01 |
2023-08-12 |
human |
| Shlomo Melme. Acromegaly pathogenesis and treatment. The Journal of clinical investigation. vol 119. issue 11. 2009-11-17. PMID:19884662. |
dysregulated growth hormone (gh) hypersecretion is usually caused by a gh-secreting pituitary adenoma and leads to acromegaly - a disorder of disproportionate skeletal, tissue, and organ growth. |
2009-11-17 |
2023-08-12 |
Not clear |
| Ana Laura Espinosa de los Monteros, Baldomero González, Guadalupe Vargas, Ernesto Sosa, Gerardo Guinto, Moisés Mercad. Surgical reintervention in acromegaly: is it still worth trying? Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 15. issue 5. 2009-11-16. PMID:19491070. |
there has not been a formal evaluation of how frequently and to what extent surgical reintervention in patients with persistently active acromegaly may achieve significant, albeit incomplete, reductions in growth hormone (gh) and insulinlike growth factor-i (igf-i) levels. |
2009-11-16 |
2023-08-12 |
Not clear |